Neurocysticercosis: Some of the essentials

Practical Neurology

Volumn 6, Issue 5, 2006, Pages 288-297

  Garcia, Hector H ^a,b,c,f   Gonzalez, Armando E ^c,d   Tsang, Victor C W ^c,e   Gilman, Robert H ^b,c  

^a INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

^e Division of Parasitic Diseases   (United States)

^f NONE   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIINFLAMMATORY AGENT; ANTIPARASITIC AGENT; CORTICOSTEROID; NICLOSAMIDE; OSMOTIC DIURETIC AGENT; OXFENDAZOLE; PRAZIQUANTEL;

ANTIGEN DETECTION; BRAIN VENTRICLE PERITONEUM SHUNT; CALCIFICATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; HEADACHE; HUMAN; HYDROCEPHALUS; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTRACRANIAL HYPERTENSION; MINIMAL RESIDUAL DISEASE; NEUROCYSTICERCOSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; REVIEW; SEIZURE; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SURGICAL TECHNIQUE; TAENIA SOLIUM; TREATMENT INDICATION;

EID: 33749026931     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2006.101253     Document Type: Review

References (61)

1. Del Brutto OH, Santilbanez R, Idrovo L, et al. Epilepsy and neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. Epilepsia 2005;46:583-7.
2. Montano SM, Villaran MV, Ylquimiche L, et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 2005;65:229-33.
3. Medina MT, Duron RM, Martinez L, et al. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama Study. Epilepsia 2005;46:124-31.
4. Garcia HH, Gonzalez AE, Gilman RH, for The Cysticercosis Working Group in Peru. Diagnosis, treatment and control of Taenia solium cysticercosis. Curr Opin Inf Dis 2003;16:411-19.
5. Canas NM, Calado SL, Vale J. [Treatment of racemose neurocysticercosis of the spine]. Rev Neurol 2005;40:544-7.
6. Rodriguez-Sanchez G, Castellanos-Pinedo F, Gimenez-Pando J, et al. [Hydrocepahlia and subarachnoid cyst due to neurocysticercosis. A new case from rural Extremadura]. Rev Neurol 2002;34:348-51.
7. Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology 2004;63:1559-64.
8. Bern C, Garcia HH, Evans C, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 1999;29:1203-9.
9. Allan JC, Velasquez-Tohom M, Garcia-Noval J, et al. Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities. Ann Trop Med Parasitol 1996;90:157-65.
10. Garcia HH, Gilman RH, Gonzalez AE, et al. Hyperendemic human and porcine Taenia solium infection in Peru. Am J Trop Med Hyg 2003;68:268-75.
11. Yoshino K. Studies on the post-embryonal development of Taenia solium: III. On the development intermediate host. J Med Assoc Formosa 1933;32:166-9.
12. Martinez MJ, De Aluja AS, Gemmell M. Failure to incriminate domestic flies (Diptera: Muscidae) as mechanical vectors of Taenia eggs (Cyclophyllidea: Taeniidae) in rural Mexico. J Med Entomol 2000;37:489-91.
13. Gilman RH, Del Brutto OH, Garcia HH, et al. Prevalence of taeniosis among patients with neurocysticercosis is related to severity of infection. The Cysticercosis Working Group in Peru. Neurology 2000;55:1062.
14. de Aluja AS, Martinez MJ, Villalobos AN. Taenia solium cysticercosis in young pigs: age at first infection and histological characteristics. Vet Parasitol 1998;76:71-9.
15. Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog Clin Parasitol 1994;4:77-116.
16. Dixon HB, Lipscomb, FM. Cysticercosis: an analysis and follow-up of 450 cases. London: Medical Research Council, 1961.
17. Escobedo F, Penagos P, Rodriguez J, et al. Albendazole therapy for neurocysticercosis. Arch Intern Med 1987;147:738-41.
18. Singh G. Neurocysticercosis in South-Central America and the Indian subcontinent. A comparative evaluation. Arq Neuropsiquiatr 1997;55:349-56.
19. Rajshekhar V, Abraham J. Disappearing CT lesions in Indian patients with epilepsy. J Neurol Neurosurg Psychiatry 1990;53:818-19.
20. Rajshekhar V. Etiology and management of single small CT lesions in patients with seizures: understanding a controversy. Acta Neurol Scand 1991;84:465-70.
21. Singh MK, Garg RK, Nath G, et al. Single small enhancing computed tomographic (CT) lesions in Indian patients with new-onset seizures. A prospective follow-up in 75 patients. Seizure 2001;10:573-8.
22. Kalra V, Dua T, Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr 2003;143:111-14.
23. Gogia S, Talukdar B, Choudhury V, et al. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg 2003;97:416-21.
24. Garcia HH, Harrison LJ, Parkhouse RM, et al. A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis. The Cysticercosis Working Group in Peru. Trans R Soc Trop Med Hyg 1998;92:411-14.
25. Garcia HH, Del Brutto OH, Nash TE, et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 2005;72:3-9.
26. Del Brutto OH, Santibanez R, Noboa CA, et al. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992;42:389-92.
27. Nash TE, Patronas NJ. Edema associated with calcified lesions in neurocysticercosis. Neurology 1999;53:777-81.
28. Nash TE, Del Brutto OH, Butman JA, et al. Calcific neurocysticercosis and epileptogenesis. Neurology 2004;62:1934-8.
29. Lobato RD, Lamas E, Portillo JM, et al. Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations. J Neurosurg 1981;55:786-93.
30. Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg 1987;66:686-9.
31. Rangel R, Torres B, Del Bruto O, et al. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg 1987;36:387-92.
32. do Amaral LL, Ferreira RM, da Rocha AJ, et al. Neurocysticercosis: evaluation with advanced magnetic resonance techniques and atypical forms. Top Magn Reson Imaging 2005;16:127-44.
33. Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989;159:50-9.
34. Allan JC, Wilkins PP, Tsang VC, et al. Immunodiagnostic tools for taeniasis. Acta Trop 2003;87:87-93.
35. Del Brutto OH. Is the course of neurocysticercosis modified by treatment with anthelmintic agents? Arch Intern Med 1997;157:128-30.
36. Sotelo J, del Brutto OH, Penagos P, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990;237:69-72.
37. Takayanagui OM. Albendazole therapy for neurocysticercosis. Neurology 1998;50:834-5.
38. Spina-Franca A, Nobrega JP. [Neurocysticercosis and praziquantel]. Rev Paul Med 1980;95:34-6.
39. Robles C, Chavarria Chavarria M. [Report of a clinical case of cerebral cysticercosis treated medically with a new drug: praziquantel]. Salud Publica Mex 1979;21:603-18.
40. Proano JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001;345:879-85.
41. Bang OY, Heo JH, Choi SA, et al. Large cerebral infarction during praziquantel therapy in neurocysticercosis. Stroke 1997;28:211-13.
42. Bergsneider M, Holly LT, Lee JH, et al. Endoscopic management of cysticercal cysts within the lateral and third ventricles. J Neurosurg 2000;92:14-23.
43. Jeri C, Gilman RH, Lescano AG, et al. Species identification after treatment for human taeniasis. Lancet 2004;363:949-50.
44. Sarti E, Schantz PM, Avila G, et al. Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg 2000;94:85-9.
45. Allan JC, Velasquez-Tohom M, Fletes C, et al. Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs. Trans R Soc Trop Med Hyg 1997;91:595-8.
46. Cruz M, Davis A, Dixon H, et al. Operational studies on the control of Taenia solium taeniasis/cysticercosis in Ecuador. Bull World Health Organ 1989;67:401-7.
47. Gonzalez AE, Gauci CG, Barber D, et al. Vaccination of pigs to control human neurocysticercosis. Am J Trop Med Hyg 2005;72:837-9.
48. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004;350:249-58.
49. Botero D, Uribe CS, Sanchez JL, et al. Short course albendazole treatment for neurocysticercosis in Columbia. Trans R Soc Trop Med Hyg 1993;87:576-7.
50. Rajshekhar V. Rate of spontaneous resolution of a solitary cysticercus granuloma in patients with seizures. Neurology 2001;57:2315-17.
51. Del Brutto OH, Roos KL, Coffey CS, et al. Albendazole and praziquantel therapy for neurocysticercosis: a meta-analysis of randomized trials. Ann Intern Med 2006;145:43-51.
52. Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994;44:1706-9.
53. Scheel CM, Khan A, Hancock K, et al. Serodiagnosis of neurocysticercosis using synthetic 8-kD proteins: comparison of assay formats. Am J Trop Med Hyg 2005;73:771-6.
54. Levine MZ, Calderon JC, Wilkins PP, et al. Characterization, cloning, and expression of two diagnostic antigens for Taenia solium tapeworm infection. J Parasitol 2004;90:631-8.
55. Correa D, Sandoval MA, Harrison LJ, et al. Human neurocysticercosis: comparison of enzyme immunoassay capture techniques based on monoclonal and polyclonal antibodies for the detection of parasite products in cerebrospinal fluid. Trans R Soc Trop Med Hyg 1989;83:814-16.
56. Brandt JR, Geerts S, De Deken R, et al. A monoclonal antibody-based ELISA for the detection of circulating excretory-secretory antigens in Taenia saginata cysticercosis. Int J Parasitol 1992;22:471-7.
57. Wilkins PP, Allan JC, Verastegui M, et al. Development of a serologic assay to detect Taenia solium taeniasis. Am J Trop Med Hyg 1999;60:199-204.
58. Pretell EJ, Martinot C, Jr, Garcia HH, et al. Differential diagnosis between cerebral tuberculosis and neurocysticercosis by magnetic resonance spectroscopy. J Comput Assist Tomogr 2005;29:112-14.
59. Braga F, Rocha AJ, Gomes HR, et al. Noninvasive MR cisternography with fluid-attenuated inversion recovery and 100% supplemental O(2) in the evaluation of neurocysticercosis. AJNR Am J Neuroradiol 2004;25:295-7.
60. Guo DM, Xie SP, Jia JP. [Therapeutic efficacy of praziquantel, albendazole and a combination of the two drugs in cysticercosis]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003;21:187-8.
61. Gonzales AE, Garcia HH, Gilman RH, et al. Effective, single-dose treatment or porcine cysticercosis with oxfendazole. Am J Trop Med Hyg 1996;54:391-4.